DENTAL SOLUTIONS

commentary on:

A Retrospective, Single Centre Clinical Evaluation Using Peek

Frameworks for Full Arch Implant Supported Prosthetics
commentary author: Marcus Jarman-Smith, PhD – Invibio Biomaterial Solutions
original presenter: Dr Bernd Siewert, Clinica Somosaguas, Madrid, Spain
keynote speech: B. Siewert (2017), PEEK in Dental Prosthetics (PEEK in der zahnärztlichen Prothetik
Warum? Wann? Wie?), SSO Dental Meeting, Lugano, Switzerland, 11 February 2017
level of evidence: Level 3 Retrospective Cohort Study

Copyright ©2017 Juvora Ltd, an Invibio company. Supporting data provided in references 1-10

Summary addition, scores were collated to measure the oral health

There is increased interest in the long term clinical
outcomes and quality of life of patients treated with a
high performance polymer for the framework material for
full-arch implant-supported dental prosthetics, rather than
the traditionally used metal or ceramic materials.
Dr Bernd Siewert has been in private practice
for over 20 years. Since 2007, he’s been an
instructor at Germany’s International Training
Center for Dental Implantology (IFZI), and
authored and spoken internationally about his
specialty, implantology.11
Dr Siewert reported on his retrospective, single center
clinical study using JUVORA frameworks for full-arch
implant-supported prosthetics, made from PEEK-OPTIMA™
high performance polymer. Dr Siewert conducted clinical
and radiological assessments to measure the survival
rates of the dental implants and prosthetics, rate of bone
loss and the incidence of any biological complications. In
and patient quality of life and the satisfaction of patients
fitted with a PEEK-based prosthetic.
The retrospective data review investigated 21 patients
which corresponded to a total of 96 dental implant
fixtures. Patients were treated with full-arch implant-
supported prosthetics manufactured with an internal
substructure made from Invibio’s PEEK-based polymer.
The average follow-up post-prosthetic placement was
56 months (4 years, 8 months) ranging from the shortest
time of 1 year and 2 months to the longest time of 8 years
and 9 months.
Key Findings
Dental implant fixture survival rate was reported as high
as 99%, and PEEK-based prosthetic survival rate was 100%
versus 89-95%1,2 and 92%3,4 for titanium5 respectively. An
average bone loss of 0.2 mm (+ 1.0) on the mesial aspect
and 0.3 mm (+ 0.8) on the distal aspect was observed
versus 1-1.5mm6,7 for titanium. Patient Peri-Implantitis
incidence was low at 1% versus 10%1,8 for titanium. The

PAGE 1
 DENTAL SOLUTIONS

mean total oral health and patient quality of life score

about the author
was 3.1 points (± 3.3), with patient satisfaction deemed
“extremely satisfactory”. For titanium the score averaged
at 15.9,10 Overall, when compared with the literature values
of Titanium, JUVORA frameworks for full-arch implant- Marcus Jarman-Smith, PhD
support dental prosthetics showed: Dr Marcus Jarman-Smith
• Up to 10% better implant survival rate is a Strategic Marketing
• Up to 5x less bone loss Manager with Invibio
Biomaterial Solutions. He
• Up to 10x less incidence of Peri-Implantitis
has worked specifically on
• Up to 8% better prosthetic survival rate
medical applications for the
• Nearly 3x better mean total score for oral health high performance polymer
and patient quality of life PEEK (polyetheretherketone)
Commentary for dental applications, for
over a decade. In 2001, he received a PhD in chemical
These results from a retrospective, single center study
engineering, tissue engineering and biomaterials from
are limited, but do provide some initial clinical insight
the University of Bath, in the United Kingdom.
into the long-term outcomes and potential benefits of
using a more shock absorbing high performance polymer
substructure for full-arch implant borne prosthetics.

REFERENCES
1. Aglietta M et al. A systematic review of the survival and complication rates of implant supported fixed dental prostheses with cantilever extensions after an
observation period of at least 5 years. Clin Oral Implants Res 2009; 20:441-451.
2. E. Behrens, et al., Zirconium Implants: in vivo and in vitro results, SKY Meeting 2012, Sofitel Munich Bayerpost, 26-28. April 2012.
3. Pjetursson BE et al. Comparison of survival and complication rates of tooth-supported fixed dental prostheses (FDPs) and implant-supported FDPs and single
crowns (SCs). Clin Oral Implants Res. 2007 Jun;18 Suppl 3:97-113.
4. Papaspyridakos P et al. A systematic review of biologic and technical complications with fixed implant rehabilitations for edentulous patients. Int J Oral Maxillofac
Implants 2012; 27:102-110.
5. Comparison with Titanium was based on literature values. See value references for the list of literature used.
6. Geraets W et al. Annual bone loss and success rates of dental implants based on radiographic measurements. Dentomaxillofac Radiol. 2014;43(7):20140007.
7. Koller CD et al. Parameters associated with marginal bone loss around implant after prosthetic loading. Brazilian Dental Journal (2016) 27(3): 292-297.
8. Heitz-Mayfield et al., The therapy of peri-implantitis: a systematic review, Int J Oral Maxillofac Implants 2014;29 Suppl:325–345.
9. Babbush CA. Posttreatment quantification of patient experiences with full-arch implant treatment using a modification of the OHIP-14 questionnaire. J Oral
Implantol. 2012 Jun;38(3):251-60.
10. Sung-HeeOh et al., Comparison of fixed implant-supported prostheses, removable implant-supported prostheses, and complete dentures: Patient satisfaction
and oral health-related quality of life, Clinical Oral Implants Research 27(2), October 2014.
11. Since 2012, Dr. Siewert has provided ad hoc consultancy services to Juvora Ltd, an Invibio Company.

Copyright ©2017 Juvora Ltd, an Invibio company. JUVORA™, INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group
of companies. All rights reserved.

PAGE 2
Invibio Ltd.
Victrex Technology Centre
Hillhouse International
Thornton-Cleveleys
Lancashire
FY5 4QD, UK
Tel: +44 (0) 1253 898 000
FAX: +44 (0) 1253 898 001
Invibio Inc.
300 Conshohocken State Road
West Conshohocken, PA
19428
USA
Toll Free: 866-INVIBIO (468-4246)
Tel: (484) 342-6004
Fax: (484) 342-6005

For further information please email us at info@invibio.com

or visit our website at:

Invibio.com

Victrex plc and/or its group companies (“Victrex plc”) believes that the information in this document is an accurate description of the typical
characteristics and/or uses of the product or products, but it is the customer’s responsibility to thoroughly test the product in each specific
application to determine its performance, efficacy, and safety for each end-use product, device or other application. Suggestions of uses should
not be taken as inducements to infringe any particular patent. The information and data contained herein are based on information we believe
reliable. Mention of a product in this document is not a guarantee of availability.

Victrex plc reserves the right to modify products, specifications and/or packaging as part of a continuous program of product development. Victrex
plc makes no warranties, express or implied, including, without limitation, a warranty of fitness for a particular purpose or of intellectual property
non-infringement, including, but not limited to patent non-infringement, which are expressly disclaimed, whether express or implied, in fact or
by law.

Further, Victrex plc makes no warranty to your customers or agents, and has not authorized anyone to make any representation or warranty
other than as provided above. Victrex plc shall in no event be liable for any general, indirect, special, consequential, punitive, incidental or similar
damages, including without limitation, damages for harm to business, lost profits or lost savings, even if Victrex has been advised of the possibility
of such damages regardless of the form of action.

Supporting information is available on request for all claims referenced in this document.

Copyright ©2017 Invibio Ltd.  INVIBIO™, JUVORA™ PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group
companies.  All rights reserved.